Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Information source: Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Multiple Myeloma in Relapse; Multiple Myeloma, Refractory
Intervention: Pomalidomide (Drug); Cyclophosphamide (Drug); Dexamethasone (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Ajai Chari Official(s) and/or principal investigator(s): Ajai Chari, MD, Principal Investigator, Affiliation: Icahn School of Medicine at Mount Sinai
Overall contact: Lisa La, MS, Phone: 212-241-7873, Email: lisa.la@mssm.edu
Summary
This study is being done to learn more about the drug, pomalidomide and to gather data on
its safety and side effects when used in combination with commercially available
cyclophosphamide and dexamethasone. This combination is considered experimental and has not
been approved by the FDA.
Pomalidomide is a third generation immunomodulatory (IMiDs) agent, which is a more potent
version of thalidomide and lenalidomide drugs that have been approved by the United States
Food and Drug Administration [FDA] for the treatment of MM. In February 2013, pomalidomide
was also approved by the FDA for patients with MM who have had more than 2 types of therapy.
Pomalidomide is taken orally as capsules, and cyclophosphamide and dexamethasone are also
taken orally as tablets in this study. Cyclophosphamide and dexamethasone are commercially
available and are often used in combination with other drugs to treat Multiple Myeloma.
Preliminary data from both the laboratory and patient studies suggest that this combination
of drugs is more effective than pomalidomide and dexamethasone alone. However, the regimen
being used in this study, which consists of daily cyclophosphamide, also permits support of
low blood counts with either injections or transfusions as needed.
Clinical Details
Official title: A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Best overall response rate (ORR)
Secondary outcome: Stringent complete response (sCR)Complete response (CR) Very good partial response (VGPR) Partial response (PR) Time to progression (TTP) Duration of response (DOR) Clinical benefit response (CBR) Progression free survival (PFS) Overall survival (OS)
Detailed description:
This is an open label, single center, phase II study of a combination of pomalidomide, daily
low dose oral cyclophosphamide, and dexamethasone in patients with relapsed/refractory
multiple myeloma. The three oral drugs will be given in 28-day cycles: Pomalidomide 4 mg
daily x 21 days; cyclophosphamide 50 mg BID x 21 days; and dexamethasone 40 mg weekly x 3
(20 mg weekly if the patient aged ≥ 75 years old). Subjects meeting eligibility criteria
with ANC < 1000/µL and platelet count < 50,000/µL will start at dose level - 1 of both
pomalidomide (3 mg daily) and cyclophosphamide (50 mg daily). G-CSF and platelet transfusion
support is permitted if needed.
Dose reduction for hematologic toxicity will begin with cyclophosphamide and then
subsequently alternate with pomalidomide until a subject cannot tolerate dose level - 2 of
both agents - in which case subject would come off study. If subject has 2 or more
concurrent toxicities that are potentially attributable to both agents (e. g. hematologic
toxicity) then dose modification guidelines will be followed with dose reduction being done
sequentially with one agent at a time, unless in the opinion of the investigator, both
agents required concurrent dose reduction.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Disease related:
- Patients must have a history of symptomatic multiple myeloma according to the IMWG
criteria
- Patients must have received at least two prior lines of therapy and also must be
refractory to lenalidomide.
- Patient has relapsed or relapsed/refractory MM.
- Patients must currently have measurable disease, as defined as:
1. Serum M-protein ≥ 0. 5 g/dL
2. Urine M-protein ≥ 200 mg/24 hours
3. Serum free light chain assay: involved FLC level ≥ 10 mg/dl provided serum FLC
ratio is abnormal
4. If no monoclonal protein is detected, then > 30% monoclonal bone marrow plasma
cells
Demographic:
- Male or female adults ≥ 18 years old
- Able to sign informed consent and to comply with the protocol
- Life expectancy > 12 weeks
- ECOG performance status ≤ 2
- All study participants must be registered into the mandatory POMALYST REMS program,
and be willing and able to comply with the requirements of the POMALYST REMS program.
Laboratory
- ANC ≥ 1000/µL
- Platelets ≥ 50,000/µL (Patients with plasma cells 50% of bone marrow nucleated
cells, and platelets ≥ 30,000/µL will be permitted regardless of the baseline ANC)
- Cr < 3
- AST ≤ 2. 5 x ULN
- ALT ≤ 2. 5 x ULN
- Serum Bilirubin ≤ 1. 5 x ULN (except patients with Gilbert's syndrome who must have a
total bilirubin of <3 time ULN)
Other
- Females of childbearing potential must have a negative serum or urine pregnancy test
with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again
within 24 hours of starting pomalidomide and must either commit to continued
abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
control at least 28 days before taking pomalidomide.
Exclusion Criteria:
- Previous treatment with pomalidomide
- Patients who received chemotherapy or radiation therapy to 30% of marrow-bearing
bone within ≤ 2 weeks or experimental agent/therapy within 4 weeks prior to starting
study treatment; or who have not yet recovered from side effects of such therapies
- Known hypersensitivity to thalidomide or lenalidomide
- The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide, lenalidomide or similar drugs
- Other concurrent severe and/or uncontrolled medical conditions including abnormal
laboratory values that could cause unacceptable safety risks or compromise compliance
with the protocol
- Patients for whom prophylactic anticoagulation therapy is not an option unless due to
thrombocytopenia
- Patients who received allogenic stem cell transplantation < 12 months prior to
entering the study or show evidence of active graft-versus-host disease that requires
immunosuppressive therapy
- Patients with existing peripheral neuropathy grade > 2
- Patients with an active malignancy requiring treatment in the next 12 months (except
for basal or squamous cell carcinoma, or in situ cancer of the cervix or breast, and
asymptomatic prostate cancer)
- Patients with known positivity for HIV or active hepatitis B or C
- Corticosteroid therapies of > 20 mg/day prednisone, > 4 mg/day dexamethasone, > 80
mg/day hydrocortisone, or equivalent. Oral, inhaled, or topical steroids are allowed
during study as long as it does not exceed 80 mg/day hydrocortisone.
Locations and Contacts
Lisa La, MS, Phone: 212-241-7873, Email: lisa.la@mssm.edu
Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States; Recruiting Ajai Chari, MD, Principal Investigator
Additional Information
Starting date: June 2014
Last updated: June 2, 2015
|